Don’t invest unless you’re prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 minutes to learn more.

SFC invests in AI startup Intoolab

Alex Batlle Bosch, Brand Manager Since 2016, Alex has led SFC Capital's digital communications, leveraging her background in social media management and creative work.
Share on

Startup Funding Club has invested in Tzager, Intoolab’s AI Biomedicine scientist.

Startup Funding Club (SFC) has recently closed a seed investment round into Artificial Intelligence startup Intoolab. The company has developed a platform where researchers, R&D employees, professors, and students work in research projects by using Tzager, one of the first artificial scientists that is trained to understand the field of Biomedicine.

AI agent/scientist Tzager is under development in collaboration with research teams from some of the biggest universities and research centres globally. Its creators aim to shape the first steps towards a true AI agent that can connect the knowledge of the field of Biomedicine to real life needs for Pharmaceuticals, Research Centres, and the critical sector of Medicine as a whole.

The team has been working on this technology since 2016, and has been shortlisted in top lists of startup events and competitions as WebSummit, Startup Bootcamp (Top 20), Startup Grind (Top 50) and Webit (Top 100). Furthermore, Intoolab’s CEO, Nikos Tzagkarakis has been working closely and been invited as a speaker in university events at Imperial College, CASS Business School, Liverpool University (London), and Aegean College just to name a few.

With the funding received from its seed round – which includes investments from both SFC’s early stage funds and the SFC Angel Network –, Intoolab will support the development of AI scientist Tzager. The company also aims to use the funds to establish its presence in the UK and European Biomedicine sector, focusing on the needs of pharmaceutical companies and research centres.

Nikos Tzagkarakis, CEO at Intoolab said: “We are thrilled to be part of such an important portfolio and to work closely with such a great team like SFC. Since the first time we met, Stephen Page showed us that we understand each other and share the same ambition towards global reach and technological excellence. Our main goal is to show the Medicine world that Intoolab and Tzager will soon be the closest they can get to true AI – especially when talking about drug discovery. You cannot have better scientists than those that can process millions of data in minutes, while at the same time understanding the whole process from a research objective to its completion. This is what we do.”

Stephen Page, CEO at SFC said: “It was obvious when we first met the Intoolab team that they had something very special. Their Tzager product will bring the world's medical knowledge into the grasp of students and researchers everywhere. The "wikipedia" of medical knowledge – and we are delighted to be part of Intoolab’s journey.”

Subscribe Here!

Related Articles

Startup Funding Club raises £250,000 of SEIS and EIS funds for on-demand insurance solutions provide...
Startup Funding Club invests in 25 companies across various sectors through its 2017 SEIS/EIS Funds
Retail analytics startup Shoppar receives £300,000 of SEIS & EIS funds and marks the first co-invest...

DISCLAIMER:
SFC Capital Ltd (SFC) is an appointed representative of SFC Capital Partners Ltd which is authorised and regulated by the Financial Conduct Authority (‘FCA’) in the United Kingdom (FRN 736284). This website is intended for professional investors only; any reproduction of this information, in whole, or part, is prohibited. The content is for information purposes only and should not be used or considered as an offer or solicitation to purchase or sell any securities.

Investment in early-stage companies involves risks such as illiquidity, lack of dividends, loss of investment and dilution. Investment in SEIS/EIS eligible companies should be considered as part of a diversified portfolio. The availability of tax relief depends on individual circumstances and may change in the future. The availability of tax relief depends on the company invested in maintaining its SEIS/EIS qualifying status. There is no assurance that the investment objectives of any investment opportunity will be achieved or that the strategies and methods described herein will be successful. The investment products cited herein may place capital at risk and therefore investors may not get back the full amount invested. Past performance is not necessarily a guide to future performance and the value of an investment may go down as well as up. Investors may not get back the full amount invested. Companies’ pitches for investment are not offers to the public and investments can only be made by members of SFC Capital. SFC Capital takes no responsibility for this information or for any recommendations or opinions made by the companies. Neither SFC Capital nor any of its employees provide any financial or tax advice in relation to the investments and investors are recommended to seek independent financial and tax advice before committing. This website is not directed at or intended for publication or distribution to any person (natural or legal) in any jurisdiction where doing so would result in contravention of any applicable laws or regulations. No warranties or representations of any kind are expressed or implied herein. This material is confidential and is the property of SFC Capital.

© SFC Capital - 2024